BioSante Pharmaceuticals, Inc. (BPAX) Licenses Vaccine to Aduro BioTech
Yesterday, BioSante Pharmaceuticals, Inc. announced that it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, for use in combination with Aduro’s proprietary vaccine platform based on Listeria monocytogenes (Lm). BioSante will receive milestone and royalty payments after commercialization of combination cancer vaccines using BioSante’s cancer vaccine technology; Aduro also has an option to additional BioSante Cancer Vaccine indications, all for use in combination with its proprietary vaccine platform. CRS-207 is Aduro’s lead Lm-based therapeutic and has been engineered to express the tumor-associated antigen mesothelin. CRS-207 was evaluated in a Phase I…